FDA Approves Treatment for Wider Range of Patients with Heart Failure
The Pharma Data
FEBRUARY 24, 2022
Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults. Jardiance was originally approved by the FDA in 2014 as a supplement to diet and exercise to improve glucose control in adults with type 2 diabetes.
Let's personalize your content